🔗 Share this article

While the United States continues making historic changes to its vaccination schedules, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning Covid vaccinations in the global health crisis and has concentrated on potential fatalities following COVID-19 immunization in her short time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Schedule

Public health authorities planned to announce sweeping changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s immunization schedule, sources say – a major change that would put the US at odds with many the world with little proof for benefit. The announcement has been postponed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this year.

A New Direction at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for ending certain pediatric shot schedules in the US to become more in line with Denmark's approach, a country with universal health coverage and a population roughly the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Concerns Over Qualifications

Dr. Høeg has little discernible experience in medication creation, oversight or leadership, which has been typical for previous directors of the CBER. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She appears not to have the requisite experience” for overseeing the CDER, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Past directors of CBER would “be deeply familiar with legal statutes and the science of drug development”, said Janet Woodcock. “Clearly, she lacks the type of experience that previous people who headed CBER have had.”

This division has an immense range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just focuses on the innovative therapies, but the generic drug division clears numerous generic medications. There is also a biosimilars program, non-prescription drug unit and other areas, and every single one have to be managed,” Dr. Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant administrative element to the role, which supervises over 5,000 employees. “It is a huge administrative position, if you perform it correctly,” Woodcock added.

Agency Reaction and Controversial Policies

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among agency officials on immunizations, a spokesperson responded that the “concerns stem from inaccurate assumptions”.

“Her resume matches the functions of her position,” the representative stated, noting the time Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a disputed one-day drug-approval program that reportedly worried her predecessors. “How are these medications being selected for this voucher program? Who takes the calls?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he remarked, “the FDA looks to be trending towards laxer rules of most medications, with the exception of immunizations.”

Public Track Record on Immunizations

Concerning vaccines, Høeg has a more documented, if troubling, track record, Howard said. She published a research paper using non-validated crowd-sourced reports to assess the rate of heart inflammation after COVID-19 vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are more dangerous than they are.

Among her “desired changes” for the new administration encompassed changing regulations for novel immunizations and halting “unnecessary” immunizations, she stated following the vote on a online show. At the agency, Høeg has reportedly floated the idea of excluding adolescent males from obtaining Covid vaccinations.

“She is an all-around ideologue who commences with her preconceived notions and works backwards to accommodate the data in a very disingenuous, dishonest way,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined other skeptics, {like|